Matritech gets grant for cancer tests:
This article was originally published in Clinica
Matritech has been awarded a Small Business Innovation Research Grant from the National Cancer Institute for the further development of Nuclear Matrix Protein (NMP) tests for the detection and management of bladder and colon cancer. Matritech is working on tests based on Nuclear Mitotic Apparatus which are believed to improve the clinical accuracy of blood and urine-based tests. The US company has developed two tests: NMP22 for bladder cancer which received US marketing approval in 1996; and the NuMA for colon cancer which was submitted to the FDA in October last year.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.